NeuroPace Beats Q2 Revenue, Raises 2026 Guidance on RNS Adoption
NPCE sits 99% above its 52-week low of $7.563.
Summary
NeuroPace delivered Q2 revenue of $22.83M, edging past the $22.65M consensus, and raised its full-year 2026 revenue guidance to $99.5M-$101.5M. Gross margin and adjusted EBITDA loss guidance also improved, reflecting stronger RNS System adoption and commercial expansion. The company reached new highs in active prescribers, accounts, and patient pipeline, signaling growing market penetration. This follows the July FDA setback for the IGE indication expansion, making the core epilepsy business performance critical. The raised outlook and narrowing losses suggest the base business is gaining momentum despite the regulatory overhang.
At the time of this announcement, NPCE was trading at $15.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $513.1M. The 52-week trading range was $7.56 to $19.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.